### (19) World Intellectual Property Organization International Bureau



### 

### (43) International Publication Date 27 September 2001 (27.09.2001)

PCT

### (10) International Publication Number WO 01/70700 A1

C07D 231/06, (51) International Patent Classification<sup>7</sup>: 409/04, 401/04, Λ61K 31/415, Λ61P 25/04, 9/00, C07D 231/08

Bernardus, J.; C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL).

(74) Agent: MUIS, Maarten; Octrooibureau Zoan B.V., P.O. Box 140, NL-1380 AC Weesp (NL).

(22) International Filing Date: 22 March 2001 (22.03.2001)

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,

(25) Filing Language:

(21) International Application Number:

English

PCT/EP01/03247

(26) Publication Language:

English

(30) Priority Data:

00201032.0 23 March 2000 (23.03.2000) EP 1014728 23 March 2000 (23.03.2000)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: SOLVAY PHARMACEUTICALS B.V. [NL/NL]; C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL).

**Published:** 

with international search report


UA, UG, UZ, VN, YU, ZA, ZW.

(72) Inventors: LANGE, Josephus, H., M.; C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL). KRUSE, Cornelis, G.; C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL). TIPKER, Jacobus; C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL). TULP, Martinus, T., M.; C.J. van Houtenlaan 36, NL-1381 CP Weesp (NL). VAN VLIET,

(1)

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

### (54) Title: 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB $_1$ -ANTAGONISTIC ACTIVITY



(i)





(iii)





(iv) (v)

(57) Abstract: The present invention relates to a group of novel 4,5-dihydro-1H-pyrazole derivatives which are potent antagonists of the cannabis CB<sub>1</sub>-receptor. The compounds have general formula (I) wherein R and R<sub>1</sub> are the same or different and represent phenyl, thienyl or pyridyl which groups may be substituted with 1, 2 or 3 substituents Y or R and/or  $R_1$  represent naphtyl,  $R_2$  represents hydrogen, hydroxy, C<sub>1-3</sub>-alkoxy, acetyloxy or propionyloxy, Aa represents one of the groups (i), (ii), (iii), (iv) or (v), Bb represents sulfonyl or carbonyl, R<sub>3</sub> represents benzyl, phenyl, thienyl or pyridyl which may be substituted with 1, 2 or 3 substituents Y or R<sub>3</sub> represents C<sub>1.8</sub> branched or unbranched alkyl or C<sub>3.8</sub> cycloalkyl, or R<sub>3</sub> represents naphtyl.

(ii)

### 4,5-Dihydro-1H-pyrazole derivatives having CB1-antagonistic activity

The present invention relates to a group of novel 4,5-dihydro-1H-pyrazole derivatives, to methods for the preparation of these compounds, and to pharmaceutical compositions containing one or more of these compounds as an active component.

The above mentioned 4,5-dihydro-1H-pyrazoles are potent Cannabis-1 (CB<sub>1</sub>) receptor antagonists with utility for the treatment of psychiatric and neurological disorders.

10

15

20

25

30

35

5

Cannabinoids are present in the Indian hemp Cannabis Sativa L. and have been used as medicinal agents for centuries (Mechoulam, R.; Feigenbaum, J.J. Prog. Med. Chem. 1987, 24, 159). However, only within the past ten years the research in the cannabinoid area has revealed pivotal information on cannabinoid receptors and their (endogenous) agonists and antagonists. The discovery and the subsequent cloning of two different subtypes of Cannabinoid receptors (CB, and CB<sub>2</sub>) stimulated the search for novel cannabinoid receptor antagonists (Munro, S.; Thomas, K.L.; Abu-Shaar, M. Nature 1993, 365, 61. Matsuda, L.A.; Bonner, T.I. Cannabinoid Receptors, Pertwee, R.G. Ed. 1995, 117, Academic Press, London). In addition, pharmaceutical companies became interested in the development of cannabinoid drugs for the treatment of diseases connected with disorders of the cannabinoid system. The wide distribution of CB1 receptors in the brain, in combination with the strictly peripheral localisation of the CB2 receptor, makes the CB<sub>1</sub> receptor a very interesting molecular target for CNS-directed drug discovery in the areas of both psychiatric and neurological disorders (Consroe, P. Neurobiology of Disease 1998, 5, 534. Pop, E. Curr. Opin. In CPNS Investigational Drugs 1999, 1, 587. Greenberg, D.A. Drug News Perspect. 1999, 12, 458). Hitherto, three types of distinct CB<sub>1</sub> receptor antagonists are known. Sanofi disclosed their diarylpyrazole congeners as selective CB<sub>1</sub> receptor antagonists. A representative example is SR-141716A, which is currently undergoing Phase II clinical development for psychotic disorders (Dutta, A.K.; Sard, H.; Ryan, W.; Razdan, R.K.; Compton, D.R.; Martin, B.R. Med. Chem. Res. 1994, 5, 54. Lan, R.; Liu, Q.; Fan, P.; Lin, S.; Fernando, S.R.; McCallion, D.; Pertwee, R.; Makriyannis, A. J. Med. Chem. 1999, 42, 769. Nakamura-Palacios, E.M.; Moerschbaecher, J.M.; Barker, L.A. CNS Drug Rev. 1999, 5, 43). Aminoalkylindoles have been disclosed as CB, receptor antagonists. A representative example is lodopravadoline (AM-630), which was introduced in 1995. AM-630 is a CB<sub>1</sub> receptor antagonist, but sometimes behaves as a weak

10

15

20

25

30

partial agonist (Hosohata, K.; Quock, R.M.; Hosohata, Y.; Burkey, T.H.; Makriyannis, A.; Consroe, P.; Roeske, W.R.; Yamamura, H.I. Life Sc. 1997, 61, PL115). More recently, researchers from Eli Lilly described aryl-aroyl substituted benzofurans as selective CB<sub>1</sub> receptor antagonists (e.g. LY-320135) (Felder, C.C.; Joyce, K.E.; Briley, E.J.; Glass, M.; Mackie, K.P.; Fahey, K.J.; Cullinan, G.J.; Hunden, D.C.; Johnson, D.W.; Chaney, M.O.; Koppel, G.A.; Brownstein, M. J. Pharmacol. Exp. Ther. 1998, 284, 291). Recently, 3-alkyl-5,5'diphenylimidazolidinediones were described as cannabinoid receptor ligands, which were indicated to be cannabinoid antagonists (Kanyonyo, M.; Govaerts, S.J.; Hermans, E.; Poupaert, J.H., Lambert, D.M. Biorg. Med.Chem. Lett. 1999, 9, 2233). Interestingly, many CB, receptor antagonists have been reported to behave as inverse agonists in vitro (Landsman, R.S.; Burkey, T.H.; Consroe, P.; Roeske, W.R.; Yamamura, H.I. Eur. J. Pharmacol. 1997, 334, R1). Recent reviews provide a nice overview of the current status in the cannabinoid research area (Mechoulam, R.; Hanus, L.; Fride, E. Prog. Med. Chem. 1998, 35, 199. Lambert, D.M. Curr. Med. Chem. 1999, 6, 635. Mechoulam, R.; Fride, E.; Di Marzo, V. Eur. J. Pharmacol. 1998, 359, 1).

It has now surprisingly been found that the novel 4,5-dihydro-1H-pyrazole derivatives of the formula (I), prodrugs thereof, tautomers thereof and salts thereof


$$\begin{array}{c|c} R & R_1 \\ \hline N & R_2 \\ \hline Aa & (I) \\ Bb & \\ R_3 \end{array}$$

### wherein

R and R<sub>1</sub> are the same or different and represent phenyl, thienyl or pyridyl which groups may be substituted with 1, 2 or 3 substituents Y, which can be the same or different, from the group C<sub>1-3</sub>-alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C<sub>1-2</sub>)-amino, mono- or dialkyl (C<sub>1-2</sub>)-amido, (C<sub>1-3</sub>)-alkyl sulfonyl, dimethylsulfamido, C<sub>1-3</sub>-alkoxycarbonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, or R and/or R<sub>1</sub> represent naphtyl,

- R<sub>2</sub> represents hydrogen, hydroxy, C<sub>1-3</sub>-alkoxy, acetyloxy or propionyloxy,
- Aa represents one of the groups (i), (ii), (iii), (iv) or (v)

3



#### wherein

5

10

15

20

25

30

- R<sub>4</sub> and R<sub>5</sub> independently of each other represent hydrogen or C<sub>1-8</sub> branched or unbranched alkyl or C<sub>3-8</sub> cycloalkyl or R<sub>4</sub> represents acetamido or dimethylamino or 2,2,2-trifluoroethyl or phenyl or pyridyl with the proviso that R<sub>5</sub> represents hydrogen
- R<sub>6</sub> represents hydrogen or C<sub>1-3</sub> unbranched alkyl
- Bb represents sulfonyl or carbonyl,
  - R<sub>3</sub> represents benzyl, phenyl, thienyl or pyridyl which may be substituted with
     1, 2 or 3 substituents Y, which can be the same or different, or R<sub>3</sub> represents
     C<sub>1-8</sub> branched or unbranched alkyl or C<sub>3-8</sub> cycloalkyl, or R<sub>3</sub> represents naphtyl

are potent and selective antagonists of the cannabis CB<sub>1</sub>-receptor.

Due to the potent CB<sub>1</sub> antagonistic activity the compounds according to the invention are suitable for use in the treatment of psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, neurological disorders such as dementia, distonia, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, as well as for the treatment of pain disorders and other CNS-diseases involving cannabinoid neurotransmission, and in the treatment of gastrointestinal disorders and cardiovascular disorders.

The affinity of the compounds of the invention for cannabinoid CB<sub>1</sub> receptors was determined using membrane preparations of Chinese hamster ovary (CHO) cells in which the human cannabis CB<sub>1</sub> receptor is stably transfected in conjunction with [3H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [3H]-ligand, with or without addition of compounds of the invention, separation of bound and free ligand was performed by filtration over glassfiber filters. Radioactivity on the filter was measured by liquid

10

15

20

25

30

scintillation counting.

The cannabinoid CB<sub>1</sub> antagonistic activity of compounds of the invention was determined by functional studies using CHO cells in which human cannabinoid CB<sub>1</sub> receptors are stably expressed. Adenylyl cyclase was stimulated using forskolin and measured by quantifying the amount of accumulated cyclic AMP. Concomitant activation of CB<sub>1</sub> receptors by CB<sub>1</sub> receptor agonists (e.g. CP-55,940 or (R)-WIN-55,212-2) can attenuate the forskolin-induced accumulation of cAMP in a concentration-dependent manner. This CB<sub>1</sub> receptor-mediated response can be antagonised by CB<sub>1</sub> receptor antagonists such as the compounds of the invention.

At least one centre of chirality is present (at the C<sub>4</sub> position of the 4,5-dihydro-1H-pyrazole moiety) in the compounds of the formula (I). The invention relates both to racemates, mixtures of diastereomers and the individual stereoisomers of the compounds having formula (I).

The invention also relates both to the E isomer, Z isomer and E/Z mixtures of compounds having formula (I) wherein Aa has the meaning (i) or (ii) as described herein above.

The compounds of the invention can be brought into forms suitable for administration by means of usual processes using auxiliary substances and/or liquid or solid carrier materials.

The compounds of the invention having formula (III) (*vide infra*), wherein  $R_2$  represents hydrogen can be obtained according to methods known, for example: a) EP 0021506; b) DE 2529689.

A suitable synthesis for the compounds according to the present invention is the following:

Synthesis route A (for compounds having formula (I), wherein Aa has the meaning (i) or (ii) as described herein above).

### Step 1 of route A

Reaction of a compound having formula (II)

(II)

with hydrazine or hydrazine hydrate. This reaction gives a compound having formula (III)

$$\begin{array}{c|c} R & R_1 \\ N & R_2 \\ H & (III) \end{array}$$

wherein R<sub>2</sub> represents a hydroxy group. This reaction is preferably carried out in a polar solvent, such as for example ethanol. Compounds having formula (III) wherein R<sub>2</sub> represents a hydroxy group and wherein R and R<sub>1</sub> have the meaning as described herein above for compound (I) are new.

### Step 2 of route A

10

15

Reaction of a compound having formula (III) with a compound having formula (IVa) or a compound having formula (IVb)

$$R_4$$
  $R_5$   $R_7$   $R_5$   $R_7$   $R_5$   $R_7$   $R_5$   $R_7$ 

wherein R<sub>7</sub> represents a lower alkyl group, such as for example 2-methyl-2-thiopseudourea, or with a suitable salt form thereof in the presence of a base. This reaction gives a 4,5-dihydro-1H-pyrazole-1-carboxamidine derivative having formula (V)

$$\begin{array}{c|c}
R & R_1 \\
R & R_2 \\
R & R_2
\end{array}$$

$$\begin{array}{c|c}
R_1 & \\
R_2 & \\
Aa & (V)
\end{array}$$

wherein Aa has the meaning (i) or (ii) as described herein above. Compounds having formula (V) wherein Aa has the meaning (i) or (ii) as described herein above and wherein R,  $R_1$  and  $R_2$  have the meaning as described herein above for compound (I) are new.

Alternatively, a compound having formula (III) is reacted with a so-called guanylating agent. Examples of such guanylating agents are 1H-pyrazole-1-carboxamidine and its salts (for example the hydrochloride salt) and 3,5-dimethyl-1H-pyrazole-1-carboxamidine and its salts (for example the nitrate salt) and the like. This reaction gives a carboxamidine derivative having formula (V).

Alternatively, a compound having formula (III) is reacted with a so-called protected guanylating agent. Examples of such protected guanylating agents are N-(benzyloxycarbonyl)-1H-pyrazole-1-carboxamidine, N-(*tert*-butoxycarbonyl)-1H-pyrazole-1-carboxamidine and N,N'-bis-(*tert*-butoxycarbonyl)-1H-pyrazole-1-carboxamidine and the like. This reaction gives after deprotection a compound having formula (V).

### Step 3 of route A

5

10

15

20

25

30

The compound having formula (V) is reacted with an optionally substituted compound of the formula  $R_3$ -SO<sub>2</sub>X or  $R_3$ -COX, wherein  $R_3$  has the above mentioned meaning and X represents a halogen atom. This reaction is preferably carried out in the presence of a base, such as triethylamine in an aprotic solvent, such as acetonitrile. This reaction gives compound (I) wherein Bb represents a sulfonyl group or a carbonyl group, respectively.

Synthesis route A1 (for compounds having formula (I), wherein Aa has the meaning (i) or (ii) as described herein above)

### Step 1 of route A1

Reaction of a compound having formula (III)

$$\begin{array}{c|c} R & & & \\ & & & \\ N & & & \\ N & & \\ R_2 & & \\ H & & & (III) \end{array}$$

5

with a thioisocyanate derivative having formula (VI) .

10

This reaction is preferably carried out in an inert organic solvent, such as for example acetonitrile.

This reaction gives a thiocarboxamide derivative having formula (VII). Compounds having formula (VII) wherein R,  $R_1$ ,  $R_2$ ,  $R_3$  and Bb have the meaning as described herein above for compound (I) are new.

15

$$\begin{array}{c|c} R & R_1 \\ N & R_2 \\ \hline & S & \text{(VII)} \\ HN & Bb \\ & R_3 \end{array}$$

### Step 2 of route A1

20

Reaction of a compound having formula (VII) with an amine in the presence of a mercury(II) salt, such as for example HgCl<sub>2</sub>, gives a compound having formula (I) wherein Aa has the meaning (i) or (ii) as described herein above.

This reaction is preferably carried out in a polar organic solvent, such as for example acetonitrile.

25

Synthesis route A2 (for compounds having formula (I), wherein Aa has the meaning (i) or (ii) as described herein above)

15

20

8

### Step 1 of route A2

Reaction of a compound having formula III

$$\begin{array}{c|c} R & R_1 \\ N & R_2 \\ H & (III) \end{array}$$

with a carbamate ester derivative having formula (VIII).

wherein R<sub>7</sub> represents a lower alkyl group, for example methyl.

This reaction is preferably carried out in an inert organic solvent, such as for example 1,4-dioxane.

This reaction gives a 4,5-dihydropyrazole-1-carboxamide derivative having formula (IX). Compounds having formula (IX) wherein R,  $R_1$ ,  $R_2$ ,  $R_3$  and Bb have the meaning as described herein above for compound (I) are new.

$$\begin{array}{c|c} R & R_1 \\ \hline N & R_2 \\ \hline & O \\ HN & Bb \\ R_3 \end{array}$$

### Step 2 of route A2

Reaction of a compound having formula (IX) with a halogenating agent, such as for example PCI<sub>5</sub>, gives a 4,5-dihydropyrazole-1-carboximidoyl halogenide derivative having formula (X)

wherein R<sub>8</sub> represents a halogen atom, such as for example chloro. This reaction is preferably carried out in an inert organic solvent, such as for example chlorobenzene.

Compounds having formula (X) wherein R,  $R_1$ ,  $R_2$ ,  $R_3$  and Bb have the meaning as described herein above for compound (I) and wherein  $R_8$  represents a halogen atom are new.

### Step 3 of route A2

5

10

15

20

25

Reaction of a compound having formula (X) with an amine gives a compound having formula (I) wherein Aa has the meaning (i) or (ii) as described herein above.

This reaction is preferably carried out in an inert organic solvent, such as for example dichloromethane.

Synthesis route A3 (for compounds having formula (I), wherein Aa has the meaning (i) or (ii) as described herein above)

### Step 1 of route A3

Reaction of a compound having formula III

$$\begin{array}{c|c} R & R_1 \\ N & R_2 \\ H & (III) \end{array}$$

with a dithioimidocarbonic ester derivative having formula (XI).

wherein R<sub>9</sub> represents a C<sub>1-3</sub> alkyl group.

This reaction is preferably carried out in a polar organic solvent, such as for example acetonitrile.

This reaction gives a carboximidothioic ester derivative having formula (XII).

$$\begin{array}{c|c} R & R_1 \\ N & R_2 \\ \hline & S - R_9 \\ \hline & Bb \\ - & R_3 \end{array}$$
 (XIII)

wherein R<sub>9</sub> represents a C<sub>1-3</sub> alkyl group. Compounds having formula (XII) wherein R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and Bb have the meaning as described herein above for compound (I) and wherein R<sub>9</sub> represents a C<sub>1-3</sub> alkyl group are new.

### Step 2 of route A3

5

15

20

25

Reaction of a compound having formula (XII) with an amine gives a compound having formula (I) wherein Aa has the meaning (i) or (ii) as described herein above.

This reaction is preferably carried out in a polar organic solvent, such as for example methanol.

Synthesis route B (for compounds having formula (I), wherein Aa has the meaning (iii) or (iv) as described herein above)

### Step 1 of route B

Reaction of a compound having formula (III)

$$\begin{array}{c|c} R & R_1 \\ N & R_2 \\ \vdots & \vdots \\ H & (III) \end{array}$$

with a compound having formula (XIII), or a compound having formula (XIV), respectively

$$Z$$
 $R_{\epsilon}$ 
 $R_{\epsilon}$ 

wherein Bb, R<sub>3</sub> and R<sub>6</sub> have the above mentioned meanings and Z represents a so-called leaving group.

These reactions give compounds having formula (I), wherein Aa has the meaning (iii) or (iv), respectively.

Synthesis route C (for compounds having formula (I), wherein Aa has the meaning (v) as described herein above)

Step 1 of route C

Reaction of a compound having formula (III)

$$\begin{array}{c|c} R & R_1 \\ N & R_2 \\ H & (III) \end{array}$$

15

with an aziridine derivative having formula (XV), or a compound having formula (XVI), respectively

$$R_6$$
 $R_6$ 
 $NH$ 
 $Prot$ 
 $Prot$ 
 $NH$ 
 $Prot$ 
 $NH$ 
 $Prot$ 

20

25

wherein R<sub>6</sub> has the above mentioned meaning, Z represents a so-called leaving group and Prot represents a so-called protective group, such as *tert*-butoxycarbonyl, benzyloxycarbonyl and the like.

These reactions give compounds having formula (XVII)

12

(XVII)

wherein Aa has the meaning (v) as described herein above. Compounds having formula (XVII) wherein R,  $R_1$  and  $R_2$  have the meaning as described herein above for compound (I) and wherein Aa has the meaning (v) as described herein above and wherein Prot represents a so-called protective group are new.

Subsequent removal of the so-called protective group according to known methods (see for example: T.W. Greene, P.G.M. Wuts, "Protective Groups in Organic Synthesis", third edition, John Wiley & Sons, Inc., New York, 1999) gives compounds (V), wherein Aa has the meaning (v) as described herein above). Compounds having formula (V) wherein R,  $R_1$  and  $R_2$  have the meaning as described herein above for compound (I) and wherein Aa has the meaning (v) as described herein above are new.

### Step 2 of route C

5

10

15

20

25

30

The compound having formula (V), wherein Aa has the meaning (v) as described herein above, is reacted with an optionally substituted compound of the formula  $R_3$ -SO<sub>2</sub>X or  $R_3$ -COX, wherein  $R_3$  has the above mentioned meaning and X is halogen. This reaction preferably is carried out in the presence of a base, such as triethylamine in an aprotic solvent, such as acetonitrile. This reaction gives compound (I) wherein Bb represents a sulfonyl group or carbonyl group respectively.

Alternatively, the above mentioned compound having formula (V) can be reacted with a compound of the formula  $R_3$ -COOH via formation of an active ester or in the presence of a so-called coupling reagent.

The preparation of the compounds is illustrated in the following examples.

### Example I

### 3-(4-Chlorophenyl)-4,5-dihydro-4-hydroxy-4-phenyl-1H-pyrazole

2-(4-Chlorobenzoyl)-2-phenyloxirane (112 gram, 0.43 mol) is dissolved in ethanol (650 ml) at 35 °C. To the resulting stirred solution is added  $N_2H_4$ . $H_2O$  (42 ml) and the formed 3-(4-chlorophenyl)-4,5-dihydro-4-hydroxy-4-phenyl-1H-pyrazole slowly precipitates. After standing for 16 hours the crystalline material is collected by filtration and successively washed with ethanol, water and ethanol and

subsequently dried to give 3-(4-chlorophenyl)-4,5-dihydro-4-hydroxy-4-phenyl-1H-pyrazole (92 gram, 78 % yield). Melting point: 195-196 °C.

### Example II

5

10

15

20

25

30

35

# 3-(4-Chlorophenyl)-4,5-dihydro-N-((4-fluorophenyl)sulfonyl)-4-phenyl-1H-pyrazole-1-carboxamidine

Part A: A stirred mixture of 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole (5.13 gram, 20.0 mmol), 2-methyl-2-thiopseudourea hydroiodide (5.00 gram, 23.0 mmol) and pyridine (10 ml) is heated at 110 °C for 1 hour. After one night standing at room temperature diethyl ether is added and the precipitate is collected by filtration. This precipitate is washed three times with diethyl ether portions to afford a solid (9 gram). Melting point: ~230 °C. This solid is dissolved in methanol (20 ml). To the resulting solution is successively added a 2N sodium hydroxide solution (12 ml) and water (200 ml). The formed precipitate is collected by filtration, washed two times with diethyl ether and successively with diisopropyl ether. The resulting solid is dried *in vacuo* to yield 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine (5.1 gram, 88 % yield). Melting point: 187-189 °C.

Part B: To a stirred mixture of 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine (0.50 gram, 1.68 mmol) and 4-fluorophenylsulfonyl chloride (0.34 gram, 1.75 mmol) in acetonitrile (10 ml) is added N,N-dimethyl-4-aminopyridine (0.020 gram, 0.175 mmol) and triethylamine (1 ml). The resulting solution is stirred at room temperature for 30 minutes. After addition of a 2N sodium hydroxide solution and extraction with ethylacetate (400 ml), the ethylacetate layer is concentrated *in vacuo*. The resulting crude residue is further purified by means of flash chromatography (petroleum ether/diethyl ether = 1/1 (v/v), followed by ethylacetate). Subsequent concentration *in vacuo* affords solid 3-(4-chlorophenyl)-4,5-dihydro-N-((4-fluorophenyl)sulfonyl)-4-phenyl-1H-pyrazole-1-carboxamidine (0.55 gram, 72 % yield). Melting point: 214-215 °C

In an analogous manner the compounds having formula (I) listed below have been prepared:

4,5-Dihydro-N-((4-fluorophenyl)sulfonyl)-3-(4-methoxyphenyl)-4-(4-methoxyphenyl)-1H-pyrazole-1-carboxamidine: Melting point: 155-156 °C 4,5-Dihydro-3-(4-methoxyphenyl)-4-(4-methoxyphenyl)-N-((4-methoxyphenyl)sulfonyl)-1H-pyrazole-1-carboxamidine: Melting point: 148-150 °C

14

3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-N-((2,4,6-trimethylphenyl)sulfonyl)-1H-pyrazole-1-carboxamidine: Melting point: 221-222 °C 3-(4-Chlorophenyl)-4,5-dihydro-N-((4-fluorophenyl)sulfonyl)-4-hydroxy-4-phenyl-1H-pyrazole-1-carboxamidine: Melting point: 227-228 °C

5

### Example III

## 3-(4-Chlorophenyl)-4,5-dihydro-N-(1-naphtoyl)-4-phenyl-1H-pyrazole-1-carboxamidine

10

To a stirred mixture of 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine (0.75 gram, 2.50 mmol) and 1-naphtoyl chloride (0.4 ml, 2.70 mmol) in acetonitrile (15 ml) is added triethylamine (1ml). The resulting mixture is stirred at room temperature for 1 hour. After addition of a 2N sodium hydroxide solution and extraction with ethylacetate, the ethylacetate layer is concentrated *in vacuo*. The resulting crude residue is further purified by means of flash chromatography (petroleum ether/diethyl ether = 3/1 (v/v), followed by ethylacetate). Subsequent concentration *in vacuo* affords 3-(4-chlorophenyl)-4,5-dihydro-N-(1-naphtoyl)-4-phenyl-1H-pyrazole-1-carboxamidine (0.94 gram, 83 % yield). Melting point: 206-207 °C

15

20

In an analogous manner the compound having formula (I) listed below has been prepared:

3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-N-(2-pyridoyl)-1H-pyrazole-1-carboxamidine. Melting point: 118 °C (decomposition)

25

### Example IV

# N<sup>1</sup>,N<sup>1</sup>-Dimethyl-N<sup>2</sup>-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine

30

Part A: A stirred mixture of 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole (12.0 gram, 46.8 mmol), [(4-chlorophenyl)sulfonyl]dithioimidocarbonic acid dimethyl ester (CAS: 13068-12-7) (9.20 gram, 31.1 mmol) and triethylamine (15 ml) in acetonitrile (200 ml) is heated at reflux temperature for 20 hours. An additional portion of 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole (12.0 gram, 46.8 mmol) is added and the resulting mixture is heated at reflux temperature for another 16 hours. After concentration *in vacuo*, dichloromethane is added and the resulting solution is washed twice with water and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration and evaporation *in vacuo* the residue is further purified by flash chromatography (diethyl ether/ petroleum ether = 1/1 (v/v)) to give 3-(4-chlorophenyl)-N-((4-chlorophenyl)sulfonyl)-4,5-dihydro-4-phenyl-1H-

35

pyrazole-1-carboximidothioic acid methyl ester (12.5 gram, 80% yield based on [(4-chlorophenyl)sulfonyl]dithioimidocarbonic acid dimethyl ester) as an amorphous solid.

**Part B**: To a stirred mixture of 3-(4-chlorophenyl)-N-((4-chlorophenyl)sulfonyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboximidothioic acid methyl ester (4.20 gram, 8.30 mmol) in methanol (75 ml) is added dimethylamine (10 ml) and dichloromethane (75 ml) and the resulting solution is stirred at room temperature for 6 hours. Evaporation *in vacuo* and subsequent flash chromatographic purification (diethyl ether/ petroleum ether = 1/1 (v/v), followed by diethyl ether) gives a solid which is further purified by recrystallisation from diisopropyl ether to yield  $N^1,N^1$ -dimethyl- $N^2$ -((4-chloro-phenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-

1-carboxamidine (2.63 gram, 63 % yield). Melting point: 182 °C.

15

20

25

10

5

In an analogous manner the compounds having formula (I) listed below have been prepared:

N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-(3-pyridyl)-1H-pyrazole-1-carboxamidine. Melting point: 101-105 °C.

N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-(4-pyridyl)-1H-pyrazole-1-carboxamidine. Melting point: 112-115 °C. N¹,N¹-Dimethyl-N²-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-hydroxy-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: Amorphous. N-Ethyl-N-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-hydroxy-4-

phenyl-1H-pyrazole-1-carboxamidine. Melting point: 183-185 °C...

Example V

# N-Methyl-N'-(3-(trifluoromethyl)benzoyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine

Part A: To 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole (5.13 gram, 20.0 mmol) in acetonitrile (80 ml) is added 3-(trifluoromethyl)benzoylisothio-cyanate (4.62 gram, 20.0 mmol) at 0 °C and the resulting mixture is stirred for 1 hour. The formed yellow precipitate is collected by filtration and washed with a small portion of acetonitrile and water, respectively, and subsequently dried *in vacuo* to give 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-N-((3-trifluoromethyl) benzoyl)-1H-pyrazole-1-thiocarboxamide (8.26 gram, 85 % yield). Melting point: 180-182 °C.

16

**Part B**: To a stirred suspension of 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-N-((3-trifluoromethyl)benzoyl)-1H-pyrazole-1-thiocarboxamide (4.88 gram, 10.0 mmol) in acetonitrile (50 ml) is added cold methylamine (5 ml) to give a green solution. After addition of a solution of  $HgCl_2$  (3.0 gram, 11 mmol) in 25 ml acetonitrile, the resulting mixture is stirred for three hours. The precipitate is removed by filtration over hyflo and the filtrate is collected and concentrated *in vacuo*. After addition of ethylacetate and 0.5 N NaOH, the ethylacetate layer is collected, washed with saturated aqueous NaCl solution and dried over anhydrous  $Na_2SO_4$ , filtered and concentrated *in vacuo*. Chromatography (dichloromethane/acetone = 9/1 (v/v)) gives N-methyl-N'-(3-(trifluoro-methyl)benzoyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine (0.99 gram, 20 % yield) as a foam. Melting point: Amorphous.  $R_f$  (Silicagel: Dichloromethane/acetone = 9/1 (v/v)) = 0.3.

### Example VI

5

10

15

20

25

30

35

# N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine

Part A: To a solution of N-((4-chlorophenyl)sulfonyl)carbamic acid methyl ester (CAS: 34543-04-9) (2.99 gram, 12.0 mmol) and pyridine (4 ml) in 1,4-dioxane (20 ml) is added 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole (3.39 gram, 13.2 mmol) and the resulting mixture is stirred for 4 hours at 100 °C. After concentration *in vacuo* the residue is dissolved in dichloromethane, successively washed with water, 1N HCl and water, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated *in vacuo* to a volume of 20 ml. Methyl-tert-butyl ether (60 ml) is added and the resulting solution is concentrated to a volume of 20 ml. The formed crystals are collected by filtration and recrystallised from methyl-*tert*-butyl ether to give 3-(4-chlorophenyl)-N-((4-chlorophenyl)sulfonyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamide (4.75 gram, 76 % yield) Melting point: 211-214 °C.

**Part B**: A mixture of 3-(4-chlorophenyl)-N-((4-chlorophenyl)sulfonyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamide (3.67 gram, 7.75 mmol) and phosphorus pentachloride (1.69 gram, 8.14 mmol) in chlorobenzene (40 ml) is heated at reflux for 1 hour. After thorough concentration *in vacuo*, the formed N-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboximidoyl chloride is suspended in dichloromethane and reacted with cold methylamine (1.5 ml). After stirring at room temperature for 1 hour, the mixture is concentrated *in vacuo*. The residue is crystallised from diethyl ether to give

N-methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine (2.29 gram, 61 % yield). Melting point: 96-98 °C (dec.).

In an analogous manner the compounds having formula (I) listed below have been prepared:

N-Methyl-N'-((3-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl 1H-pyrazole-1-carboxamidine. Melting point: 156-160 °C.

N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(5-chloro-2-thienyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: Amorphous

N-Propyl-N'-((4-fluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: 129-138 °C.

N-(2-Propyl)-N'-((4-fluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: 110-112 °C.

N-Methyl-N'-((2-propyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: Amorphous.

10

20

25

30

35

N-(2-Propyl)-N'-((4-chlorophenyl)sulfonyl)-3-(4-pyridyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: Amorphous.

N¹-Ethyl-N¹-methyl-N²-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: 184 °C.

N¹-Ethyl-N¹-methyl-N²-((4-fluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: 173-176 °C.

N¹,N¹-Dimethyl-N²-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: 195-196 °C.

N<sup>1</sup>,N<sup>1</sup>-Dimethyl-N<sup>2</sup>-((3-methylphenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: 195-198 °C.

N<sup>1</sup>,N<sup>1</sup>-Dimethyl-N<sup>2</sup>-((3-methoxyphenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: 204-206 °C.

N-Ethyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: Amorphous.

N-Dimethylamino-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: 155-159 °C.

N-Methyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: Amorphous.

N<sup>1</sup>,N<sup>1</sup>-Dimethyl-N<sup>2</sup>-((2-methylphenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point:148-151 °C.
N-Methyl-N'-((2,4-difluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-

phenyl-1H-pyrazole-1-carboxamidine. Melting point: 85 °C.

10

15

20

25

30

35

N-Acetamido-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: Amorphous.

N-(2,2,2-Trifluoroethyl)-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: Amorphous.

N-(2-Pyridyl)-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole-1-carboxamidine. Melting point: 142-146 °C.

N-(4-Pyridyl)-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl -1H-pyrazole-1-carboxamidine. Melting point: 204-206 °C.

N-Phenyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl -1H-pyrazole-1-carboxamidine. Melting point: 158-160 °C.

### Example VII

# 3-(4-Chlorophenyl)-1-[3-((4-chlorophenyl)sulfonyl)butanoyl]-4,5-dihydro-4-phenyl-1H-pyrazole

To a stirred mixture of 3-((4-chlorophenyl)sulfonyl)butyric acid (1.85 gram, 7.00 mmol), diisopropylethylamine (3 ml) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.50 gram, 15.7 mmol) was added 3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole (3.00 gram, 11.7 mmol) and the resulting mixture was stirred for 16 hours at room temperature. After concentration *in vacuo* the resulting residue was purified by flash chromatography (petroleum ether/ diethyl ether = 1/2 (v/v), followed by diethyl ether) to give 3-(4-chlorophenyl)-1-[3-((4-chlorophenyl)sulfonyl)butanoyl]-4,5-dihydro-4-phenyl-1H-pyrazole (3.69 gram, 63 % yield) as a diastereomeric

In an analogous manner the compounds having formula (I) listed below have been prepared:

3-(4-Chlorophenyl)-1-[3-(phenylsulfonyl)propanoyl]-4,5-dihydro-4-phenyl-1H-pyrazole. Melting point: 122-123 °C.

3-(4-Chlorophenyl)-1-[3-((4-chlorophenyl)sulfonyl)propanoyl]-4,5-dihydro-4-phenyl-1H-pyrazole. Melting point: 178-181 °C.

### Example VIII

mixture. Melting point: amorphous

### 3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-1-[2-((3-(trifluoromethyl)phenyl)-sulfonyl)ethyl]-1H-pyrazole

To a stirred mixture of 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole (1.7 gram, 6.60 mmol) and collidine (2 ml) in acetonitrile (25 ml) is slowly added a solution of 2-((3-(trifluoromethyl)phenyl)sulfonyl)ethyl chloride (1.5 gram, 5.50 mmol) in acetonitrile (20 ml) and the resulting solution is heated at reflux

temperature for 16 hours. After concentration *in vacuo* the residue is dissolved in ethylacetate and washed with aqueous sodium hydrogencarbonate solution. The resulting ethylacetate layer is successively washed with 1N hydrochloric acid solution and aqueous sodium hydrogencarbonate solution.

Subsequent flash chromatographic purification (petroleum ether/ diethyl ether = 1/2 (v/v)) gives an oil which is crystallised from diisopropyl ether to afford 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1-[2-((3-(trifluoromethyl)phenyl)sulfonyl)ethyl]-1H-pyrazole (0.52 gram, 19 % yield). Melting point: 118-119 °C.

In an analogous manner the compounds having formula (I) listed below have been prepared:

3-(4-Chlorophenyl)-1-[2-(benzylsulfonyl)ethyl]-4,5-dihydro-4-phenyl-1H-pyrazole. Melting point: 161 °C.

3-(4-Chlorophenyl)-1-[2-((4-chlorophenyl)sulfonyl)ethyl]-4,5-dihydro-4-phenyl-1H-pyrazole. Melting point: Amorphous

3-(4-Chlorophenyl)-1-[2-((4-chlorophenyl)sulfonyl)ethyl]-4,5-dihydro-4-hydroxy-4-phenyl-1H-pyrazole. Melting point: 127-128 °C.

### 20 Example IX

5

10

15

25

30

35

### N-[2-(3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazol-1-yl)ethyl]-3-(trifluoromethyl)benzenesulfonamide

Part A: A stirred solution of 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole (5.00 gram, 19.5 mmol) and N-(*tert*-butoxycarbonyl)aziridine (2.00 gram, 14.0 mmol) in toluene (100 ml) is heated at reflux temperature for 16 hours. After concentration *in vacuo* the residue is purified by flash chromatography (petroleum ether/ diethyl ether = 3/1 (v/v)), followed by petroleum ether/ diethyl ether = 1/1 (v/v)). After concentration *in vacuo* the remaining oily residue is crystallised from diisopropyl ether to afford 1-[2-((*tert*-butoxycarbonyl)amino)ethyl]-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole (1.91 gram, 34 %). Repeated crystallisations from the mother liquor afforded an additional amount of crystalline 1-[2-((*tert*-butoxycarbonyl)amino)ethyl]-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole (1.19 gram).

**Part B:** To a solution of 1-[2-((*tert*-butoxycarbonyl)amino)ethyl]-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole (1.91 gram, 4.8 mmol) in dichloromethane (50 ml) is added trifluoroacetic acid (5 ml) and the resulting solution is stirred at room temperature for 5 hours. After concentration *in vacuo* the residue is dissolved in ethylacetate and washed with 2N sodium hydroxide solution. The ethyl acetate layer is dried over magnesium sulfate, filtered and

20

5

10

concentrated *in vacuo* to afford 1-(2-aminoethyl)-3-(4-chlorophenyl)- 4,5-dihydro-4-phenyl-1H-pyrazole (1.44 gram, quantitative yield) as an oil.

**Part C:** To a solution of 1-(2-aminoethyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazole (0.56 gram, 1.87 mmol) and diisopropylethylamine in acetonitrile (20 ml) is added 3-(trifluoromethyl)phenylsulfonyl chloride (0.35 ml, 2.18 mmol) and the resulting solution is stirred at room temperature for 20 minutes. After concentration *in vacuo* the residue is dissolved in ethylacetate and washed with 2N sodium hydroxide solution. The ethylacetate layer is concentrated *in vacuo*. The resulting oil is crystallised from a small amount of diisopropyl ether to afford crystalline N-[2-(3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazol-1-yl)ethyl]-3-(trifluoromethyl)benzenesulfonamide (0.44 gram, 46 % yield). Melting point: 94-96 °C.

PCT/EP01/03247

### **Claims**

1. A compound of formula (I)

$$\begin{array}{c|c} R & R_1 \\ \hline N & R_2 \\ \hline Aa & (I) \\ Bb & \\ R_3 \end{array}$$


5

### wherein

10

15

- R and R<sub>1</sub> are the same or different and represent phenyl, thienyl or pyridyl which groups may be substituted with 1, 2 or 3 substituents Y, which can be the same or different, from the group C<sub>1-3</sub>-alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl  $(C_{1-2})$ -amino, mono- or dialkyl  $(C_{1-2})$ -amido,  $(C_{1-3})$ -alkyl sulfonyl, dimethylsulfamido, C<sub>1-3</sub>-alkoxycarbonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, or R and/or R₁ represent naphtyl,
- R<sub>2</sub> represents hydrogen, hydroxy, C<sub>1-3</sub>-alkoxy, acetyloxy or propionyloxy,
- Aa represents one of the groups (i), (ii), (iii), (iv) or (v)



20

25

### wherein

- R<sub>4</sub> and R<sub>5</sub> independently of each other represent hydrogen or C<sub>1-8</sub> branched or unbranched alkyl or C<sub>3-8</sub> cycloalkyl or R<sub>4</sub> represents acetamido or dimethylamino or 2,2,2-trifluoroethyl or phenyl or pyridyl with the proviso that R<sub>5</sub> represents hydrogen
- R<sub>6</sub> represents hydrogen or C<sub>1-3</sub> unbranched alkyl

20

25

30

35

- Bb represents sulfonyl or carbonyl,
- R<sub>3</sub> represents benzyl, phenyl, thienyl or pyridyl which may be substituted with
   1, 2 or 3 substituents Y, which can be the same or different, or R<sub>3</sub> represents
   C<sub>1-8</sub> branched or unbranched alkyl or C<sub>3-8</sub> cycloalkyl, or R<sub>3</sub> represents naphtyl and tautomers, prodrugs and salts thereof.
- 2. A compound having formula (I) as claimed in claim 1, wherein R is the group 4-chlorophenyl, R<sub>1</sub> is phenyl, R<sub>2</sub> is hydrogen, Aa is the group (i) wherein R<sub>4</sub> is hydrogen and R<sub>5</sub> is methyl, Bb is sulfonyl, and R<sub>3</sub> represents 4-chlorophenyl, and salts thereof.
- 3. A pharmaceutical composition containing at least one compound as claimed in1 as an active component.
  - 4. A method of preparing pharmaceutical compositions characterized in that a compound as claimed in claim 1 is brought in a form suitable for administration.
  - 5. Process for the preparation of compounds having formula I, characterized in that
  - a) a compound is prepared wherein R,  $R_1$ - $R_3$  and Bb have the meanings given in claim 1 and Aa is a group of the formula (i) or (ii) as defined in claim 1 by
    - reacting a compound having formula (II) with hydrazine or hydrazine hydrate to obtain a compound having formula (III), which is reacted with a compound having formula (IVa) of (IVb) to give a compound having formula (V), which is reacted with a compound of the formula R<sub>3</sub>-SO<sub>2</sub>X or R<sub>3</sub>-COX, wherein X is halogen, or
    - 2) reacting a compound having formula (III) with a thioisocyanate of the formula (VI) to produce a compound of the formula (VII), which is reacted with an amine in the presence of a mercury (II) salt, or
    - 3) reacting a compound having formula (III) with a compound of the formula

(VIII) to give a compound of the formula (IX) which is reacted with a halogenating agent to give a compound having formula (X) which is reacted with an amine, or

5

 reacting a compound having formula (III) with a compound of the formula (XI) to give a compound having formula (XII) which is reacted with an amine, or

10

b) a compound is prepared wherein R, R<sub>1</sub>-R<sub>3</sub> and Bb have the meanings given in claim 1 and Aa is a group of the formula (iii) or (iv) as defined in claim 1 by reacting a compound of the formula (III) with a compound of the formula (XIII) of (XIV), or

15

c) a compound is prepared wherein R, R<sub>1</sub>-R<sub>3</sub> and Bb have the meanings given in claim 1 and Aa is a group of the formula (v) as defined in claim 1, by reacting a compound having formula (III) with a compound having formula (XV) or (XVI) to give a compound having formula (XVII), which is deprotected to give a compound having formula (V), which is reacted with a compound having formula R<sub>3</sub>-SO<sub>2</sub>X or R<sub>3</sub>-COX wherein X is halogen or with a compound of the formula R<sub>3</sub>-COOH.

20

6. A compound of formula (III)

$$\begin{array}{c|c} R & & R_1 \\ \hline N & & R_2 \\ \hline N & & \\ H & & (III) \end{array}$$

25

wherein  $R_2$  represents a hydroxy group and wherein R and  $R_1$  have the meanings given in claim 1.

### 7. A compound of formula (V)

30

$$\begin{array}{c|c} R & R_1 \\ N & R_2 \\ \vdots & \vdots \\ Aa & (V) \\ H & \end{array}$$

wherein Aa has the meaning (i), (ii) or (v) as given in claim 1 and wherein R,  $R_1$  and  $R_2$  have the meanings given in claim 1.

### 8. A compound of formula (VII)

5

10

20

$$\begin{array}{c|c} R_1 & & \\ N & R_2 & \\ \hline & S & (VII) \\ HN & Bb & \\ R_3 & & \end{array}$$

wherein R,  $R_1$ ,  $R_2$   $R_3$  and Bb have the meanings given in claim 1.

9. A compound of formula (IX)

$$\begin{array}{c|c}
R & R_1 \\
N & R_2 \\
\hline
N & O \\
HN & Bb \\
R_3
\end{array}$$
(IX)

wherein R, R<sub>1</sub>, R<sub>2</sub> R<sub>3</sub> and Bb have the meanings given in claim 1.

10. A compound of formula (X)

$$\begin{array}{c|c} R & R_1 \\ \hline N & R_2 \\ \hline & R_8 \\ \hline & R_8 \\ \hline & R_3 \end{array} \qquad (X)$$

wherein R,  $R_1$ ,  $R_2$   $R_3$  and Bb have the meanings given in claim 1 and wherein  $R_8$  represents a halogen atom.

### 11. A compound of formula (XII)

5

$$\begin{array}{c|c} R & R_1 \\ N & R_2 \\ \hline & S - R_9 \\ \hline & Bb \\ & R_3 \end{array} \tag{XII)}$$

wherein R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and Bb have the meanings given in claim 1 and wherein R<sub>9</sub> represents a  $C_{1-3}$  alkyl group.

10

### 12. A compound of formula (XVII)

(XVII)

15

wherein R,  $R_1$  and  $R_2$  have the meanings given in claim 1 and wherein Aa has the meaning (v) as given in claim 1 and wherein Prot represents a so-called protective group.

20

13. A method of treating psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, neurological disorders such as Parkinson's disease, dementia, distonia, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, ischaemia, pain and other CNS-diseases involving cannabinoid neurotransmission, characterized in that a compound as claimed in claim 1 is used.

25

26

- 14. A method of treating gastrointestinal disorders involving cannabinoid neurotransmission, characterized in that a compound as claimed in claim 1 is used.
- 5 15. A method of treating cardiovascular disorders involving cannabinoid neurotransmission, characterized in that a compound as claimed in claim 1 is used.

### INTERNATIONAL SEARCH REPORT

Intel 1al Application No PCT/EP 01/03247

		<u> </u>								
A. CLASSII IPC 7	FICATION OF SUBJECT MATTER C07D231/06 C07D409/04 C07D401/ A61P9/00 C07D231/08	04 A61K31/415 A61P	25/04							
According to International Patent Classification (IPC) or to both national classification and IPC										
B. FIELDS SEARCHED										
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D A61K A61P										
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched										
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)										
EPO-Internal, CHEM ABS Data, WPI Data										
C. DOCUMENTS CONSIDERED TO BE RELEVANT										
Category °	Citation of document, with indication, where appropriate, of the rele	evant passages	Relevant to claim No.							
A	US 5 624 941 A (BARTH FRANCIS ET 29 April 1997 (1997-04-29) abstract 	AL)	1,13-15							
Further documents are listed in the continuation of box C.  Patent family members are listed in annex.										
*A* document defining the general state of the art which is not considered to be of particular relevance  *E* earlier document but published on or after the international filling date  *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  *O* document referring to an oral disclosure, use, exhibition or other means  *P* document published prior to the international filling date but		<ul> <li>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>"&amp;" document member of the same patent family</li> </ul>								
Date of the actual completion of the international search  7 May 2001		Date of mailing of the international search report 25/05/2001								
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  De Jong, B								
		I								

### INTERNATIONAL SEARCH REPORT

ormation on patent family members

Inte 1al Application No PCT/EP 01/03247

Patent document cited in search repor	1	Publication date		Patent family member(s)	Publication date
US 5624941	A	29-04-1997	FR	2692575 A	24-12-1993
			FR	2713224 A	09-06-1995
			FR	2713225 A	09-06-1995
			AT	149489 T	15-03-1997
			AU	4143893 A	06-01-1994
			BR	1100409 A	13-10-1999
			BR	9302435 A	11-01-1994
			CA	2098944 A	24-12-1993
			CZ	9301172 A	16-03-1994
			DE	69308395 D	10-04-1997
					15-09-1997
			DK	576357 T	
			EP	0576357 A	29-12-1993
			ES	2101258 T	01-07-1997
			FI	932891 A	24-12-1993
			GR	3023535 T	29-08-1997
			HU	64526 A,B	28-01-1994
			IL	106099 A	15-07-1998
			JP	6073014 A	15-03-1994
			MX	9303664 A	31-01-1994
			NO	932296 A	27-12-1993
			NZ	247961 A	28-08-1995
			RU	2119917 C	10-10-1998
			SK	65493 A	02-02-1994
			ZA	9304511 A	22-02-1994
			AT	154012 T	15-06-1997
			AU	685518 B	22-01-1998
			AU	7899994 A	15-06-1995
			BR	1100984 A	14-03-2000
			CA	2136893 A	21-06-1995
			CN	1110968 A,B	01-11-1995
			CZ	9403016 A	14-06-1995
			DE	69403614 D	10-07-1997
			DE	69403614 T	22-01-1998
			DK	656354 T	29-12-1997
			EP	0656354 A	07-06-1995
			ES	2105575 T	16-10-1997
			FI	945690 A	03-06-1995
			GR	3024470 T	28-11-1997
			HK	1000599 A	09-04-1998
			HU	71498 A,B	28-11-1995
			IL	,	28-10-1999
				111719 A	19-02-2001
			JP	3137222 B	
			JP	7309841 A	28-11-1995
			JP	2001026541 A	30-01-2001
			NO	944625 A	06-06-1995
			NZ	270025 A	26-09-1995
			PL	306067 A	12-06-1995
			RU	2141479 C	20-11-1999
			SG	68570 A	20-06-2000
			SI	656354 T	31-10-1997